These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12057121)

  • 21. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
    Arun B; Curti BD; Longo DL; Stevens D; Alvord WG; Gause BL; Watson T; Kopp WC; Janik JE
    Cancer J Sci Am; 2000; 6(1):21-4. PubMed ID: 10696734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the treatment of hairy-cell leukaemia.
    Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
    Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of hairy cell leukemia: an update.
    Golomb HM; Ratain MJ; Mick R; Daly K
    Leukemia; 1992; 6 Suppl 2():24-7. PubMed ID: 1349662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. My treatment approach to hairy cell leukemia.
    Naik RR; Saven A
    Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
    Saven A; Burian C; Koziol JA; Piro LD
    Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
    Öngören Ş; Eşkazan AE; Berk S; Elverdi T; Salihoğlu A; Ar MC; Başlar Z; Aydın Y; Tüzüner N; Soysal T
    Turk J Haematol; 2017 Dec; 34(4):291-299. PubMed ID: 29199176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.
    Piro LD; Ellison DJ; Saven A
    Leuk Lymphoma; 1994; 14 Suppl 1():121-5. PubMed ID: 7820043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The optimal management of hairy cell leukaemia.
    Gollard R; Lee TC; Piro LD; Saven A
    Drugs; 1995 Jun; 49(6):921-31. PubMed ID: 7543840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic advances in the treatment of hairy cell leukemia.
    Andrey J; Saven A
    Leuk Res; 2001 May; 25(5):361-8. PubMed ID: 11301103
    [No Abstract]   [Full Text] [Related]  

  • 31. Hairy cell leukaemia, its therapy and prognosis (historical review with own experiences).
    Chrobák L; Podzimek K; Zak P; Plísková L; Voglová J
    Acta Haematol Pol; 1995; 26(2 Suppl 1):56-62. PubMed ID: 7653236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hairy cell leukaemia.
    Platanias LC; Golomb HM
    Baillieres Clin Haematol; 1993 Dec; 6(4):887-98. PubMed ID: 7913637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.
    Tallman MS; Hakimian D; Variakojis D; Koslow D; Sisney GA; Rademaker AW; Rose E; Kaul K
    Blood; 1992 Nov; 80(9):2203-9. PubMed ID: 1358262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hairy cell leukemia: an elusive but treatable disease.
    Wanko SO; de Castro C
    Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience.
    Au WY; Klasa RJ; Gallagher R; Le N; Gascoyne RD; Connors JM
    Blood; 1998 Aug; 92(4):1160-4. PubMed ID: 9694703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
    Cheson BD; Vena DA; Barrett J; Freidlin B
    J Clin Oncol; 1999 Aug; 17(8):2454-60. PubMed ID: 10561309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hairy-cell leukemia.
    Lill MC; Golde DW
    Blood Rev; 1990 Dec; 4(4):238-44. PubMed ID: 1706207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
    Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
    Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
    Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
    Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.